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Abstract
Objectives—To characterize the response of the rat bladder neuromuscular system to intramural 
injection of onabotulinum toxin type A (BoNT/A) over 9 weeks using in vivo cystometry (CMG) 
and in vitro contractility (IVC).
Methods—Chronic bladder catheters were implanted in female Sprague-Dawley rats and either 
1) BoNT/A (10 units in 20μl saline) or 2) saline (20μl) was injected in 5 × 4μl doses throughout 
the bladder wall. At 1, 3, 6 and 9 weeks after injection, conscious restrained CMG was performed. 
At each time point, 25% of each group (8 BoNT/A and 4 controls) was euthanized and bladders 
harvested for IVC. We measured IVC in response to electric field stimulation, carbachol, and 
potassium chloride.
Results—In total 47 animals were included; 31 underwent BoNT/A injection, and 16 received 
sham (saline). Bladder capacities did not differ significantly between groups for each time point. 
One week after injection, BoNT/A animals exhibited significantly longer bladder contraction 
durations and lower voiding efficiencies compared to controls. By 3 weeks these values returned to 
control levels. For BoNT/A animals, contractile response to carbachol stimulation was enhanced at 
3 weeks. Otherwise there were no differences in IVC responses.
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Conclusions—One week following BoNT/A injection, prolonged bladder contractions are noted 
in rats. This may reflect supraspinal compensation for denervation by increasing the duration of 
efferent drive during voiding. After 3 weeks post injection we observed no differences in either 
CMG or IVC responses suggesting either compensatory efferent sprouting, increased gap junction 
formation, or loss of BoNT/A effect.
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INTRODUCTION
The purpose of the lower urinary tract is the storage and periodic release of urine. Storage is 
promoted via the sympathetic and somatomotor activity while voiding is governed by the 
sacral parasympathetic nervous system. Overactive bladder (OAB) and urgency urinary 
incontinence (UUI) are highly prevalent disorders of storage that negatively impact the lives 
of millions of adults.1 It is widely believed that these problems are the result of an imbalance 
of the storage and release mechanisms, reflecting inappropriate parasympathetic reflex 
pathway activity during filling. As such, treatments have historically involved the use of 
antimuscarinic agents.
A promising new treatment for OAB refractory to anticholinergic medication is 
onabotulinum toxin type A (BoNT/A), which acts on SNAP-25 to block the release of 
acetylcholine from presynaptic neurons. While the therapeutic efficacy of BoNT/A is well 
proven and the mechanism appears to involve functional denervation, there is a limited 
understanding of how the bladder neuromuscular system may compensate in response to 
BoNT/A both acutely and chronically.2,3 Early studies have shown that BoNT/A decreases 
in vivo detrusor pressure 48 hours after injection in rats with chemically-induced detrusor 
overactivity,4 inhibits in vitro detrusor contractility in bladder strips incubated with BoNT/
A,5 and decreases the release of acetylcholine and norepinephrine from autonomic 
neurons.6,7 There is also evidence to suggest that BoNT/A acts on afferent neurons to alter 
sensory signaling in the bladder.8,9 However, much remains to be discovered, including a 
further delineation of the temporal relationship between neurologic and muscular effects.
Our objective was to determine how the detrusor smooth muscle and autonomic nervous 
system respond to functional denervation with BoNT/A over a 9-week period in an intact rat 
model. By utilizing an experimental design of combined cross-sectional and longitudinal 
cystometric evaluation, we aimed to determine if changes in bladder function in vivo 
mirrored changes in detrusor smooth muscle contractility in vitro to improve our 
understanding of smooth muscle physiology and bladder neuromuscular function.
MATERIALS AND METHODS
Experimental Timeline
Experiments were performed at the Durham Veterans Affairs Medical Center (DVAMC) 
from August 2013 to March 2014. Female Sprague-Dawley rats (Charles River Laboratories, 
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Boston, MA) weighing 240 to 307 grams were used in the experiments. We observed a total 
of 47 rats for 1 to 9 weeks. A total of 31 rats received BoNT/A injection and 16 rats received 
saline injection. Testing was performed at 1, 3, 6, and 9 week time points after injection. 
Rats were housed in pairs in a temperature-controlled room with a 12:12 hour light-dark 
cycle and maintained with access to food and water ad libitum. All procedures were 
conducted with the approval of the Institutional Animal Care and Use Committee of the 
Durham Veterans Affairs Medical Center (IACUC, protocol identification A085-13-03) and 
in accordance with the National Institutes of Health Guidelines for the Care and Use of 
Laboratory Animals.
Chronic Catheter Implantation
On experimental day 0, using sterile technique in Isoflurane anesthetized rats, the bladder 
was exposed via midline abdominal incision made with a scalpel. A cystotomy was made in 
the apex of the bladder dome, a PE50 tube with flared tip was inserted into the bladder 
lumen, and secured with 5-0 silk suture.10 The free end of the catheter was tunneled 
subcutaneously to the midscapular region, and following BoNT/A or saline injection (see 
below), the catheter was flushed with saline followed by 1mg/ml gentamycin sulfate in 0.9% 
saline, flame sealed, and left in a subcutaneous midscapular pocket to be easily retrieved at 
the time of future CMG evaluations.
BoNT/A Injection
After the bladder catheter was secured in place, the bladder was filled just enough to distend 
the bladder walls for ease of injection. Ten units of BoNT/A (onabotulinum toxin type A, 
Allergan Inc., Irvine, CA, USA) in 20μl of saline or 20μl of saline alone (sham procedure for 
controls) were injected in 5 equally divided doses, one in each wall and one in the dome 
using a 25μl Hamilton syringe.11 Injection in the bladder tissues was confirmed visually by 
blebbing of the tissue at the injection site ensuring injection into all walls and the dome. We 
chose a dose of 10 units as this was above the minimal effective dose of 7.5 units 
demonstrated in a previous dose response study on female Sprague-Dawley rats.11
Post-operative Animal Care
The abdominal musculature was closed with Vicryl suture and the skin was closed with 
surgical wound clips. All animals received twice daily subcutaneous injection of 
Buprenorphine (0.5mg per animal) and Enrofloxacin (10mg per animal) for 3 and 5 days, 
respectively, after surgery.
In Vivo Cystometry
In order to detect the effect of BoNT/A injection and to allow sufficient recovery from 
surgery we performed conscious restrained cystometry on all animals starting at 1 week after 
surgery, and then at 3, 6, and 9 week time points, unless harvested for in vitro studies at a 
previous time point (see below). Animals were acclimated to the restraint by being placed in 
the Ballman restraint cage for 1 hour per day for 3 days during the week prior to the week 1 
cystometry testing. Food and water was provided ad libidum while in restraint. On day of 
cystometric testing, animals were briefly anesthetized with Isoflurane, mounted in Ballman 
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restraint cages, the catheter was exposed from the subscapular subcutaneous pocket and 
connected to an infusion pump with pressure transducer via a 4-way stopcock.10 Animals 
were allowed to recover from anesthesia, and intravesicle saline was infused at 0.1 ml/min to 
elicit spontaneous filling and voiding cycles. After a 60-minute recovery period, bladders 
were emptied and a single fill cystometrogram was performed, followed by 60 minutes of 
continuous cystometry, followed by one final bladder emptying and single filling 
cystometrogram.
True bladder capacity (TBC, mL) and postvoid residual volume (PVR, mL) were measured 
during single filling cystometrograms. TBC was defined as the volume at which a voiding 
contraction would occur after complete emptying of the bladder. PVR was obtained by 
measuring the residual bladder volume obtained after a voiding contraction was completed 
with at least two values obtained per animal per session. During the 60 minutes of 
continuous cystometry functional bladder capacity (FBC, mL), voided volume (VV, mL), 
and voiding contraction parameters were measured using LabChart 7 data collection 
software (ADInstruments, Inc. Colorado Springs, CO, USA). The assessor was masked to 
intervention. FBC was defined as the bladder volume at which a voiding contraction would 
spontaneously occur during continuous cystometry. If more than one measurement of TBC, 
FBC and/or PVR was available, we calculated the average to use in our data analysis. 
Voiding efficiency (VE) was calculated as the average FBC divided by the average TBC.
In Vitro Contractility
To further characterize the detrusor neuromuscular response after BoNT/A injection, we 
performed IVC on bladder strips. Following cystometry at each time point, 25% of the rats 
(i.e. 12 per time point) were euthanized, the bladders were excised, and placed into a tissue 
bath of oxygenated Krebs solution [mmol/L: NaCl 143.34, KCl 4.96, MgSO4 1.29, KH2PO4 
1.29, NaHCO3 10.78, glucose 11.85, and CaCl2 2.69]. Full thickness circumferential 
(equatorial) and longitudinal (full length ventral) bladder strips were harvested from each 
bladder and mounted in separate tissue baths of oxygenated Krebs solution at 37 degrees 
Celsius. Bladder strips were mounted such that tension was adjusted to 1 gram (Figure 1). 
Detrusor contractile force (DCF) was measured in response to three stimuli, performed in 
the same order for each IVC experiment with a washout period in between to allow recovery 
and return to baseline tension. The first of these was electric field stimulation (EFS), 
performed to assess neurally-mediated contractility. For EFS, frequency-response curves 
(0.5 to 32 Hz as escalating doublings) were generated by stimulating the bladder strips every 
3 minutes for 10 seconds with 0.05 millisecond pulse width at 100 Volts using an S48 
stimulator (Grass Instruments, W. Warwick, RI, USA). Second, carbamylcholine chloride 
(carbachol; ICN Biomedicals Inc., Aurora, OH, USA) was used to assess smooth muscle 
response to known quantities of cholinergic agonist. For carbachol stimulation, 
concentration-response curves were generated cumulatively with carbachol doses ranging 
from 10−1 to 103 uM administered in escalating log increments every 3–5 minutes. Finally, a 
single challenge to potassium chloride (KCl; 60mM) was used to measure inherent muscle 
contractility. Force generation was measured via tensiometer and recorded using LabChart 7 
data collection software (ADInstruments, Inc. Colorado Springs, CO, USA). For each strip, 
tissue contractility response was normalized to response to KCl 60mM stimulation, which 
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was assessed at the completion of IVC testing. The entire IVC preparation and experimental 
protocol took approximately 4–5 hours.
Statistical Analysis
Data were analyzed by two-way ANOVA with repeated measures as appropriate, and with 
Sidak’s or Tukey’s multiple comparison post-test. For all experiments, p < 0.05 defined 
significance. All statistical analyses were performed using GraphPad Prism Version 6.0 
(GraphPad Software, Inc., La Jolla, CA, USA).
RESULTS
A total of 47 animals underwent baseline injection and catheter implantation. This total 
included 12 animals per time point (8 BoNT/A and 4 controls) with the exception of the 3-
week group, which had 11 animals (4 control and 7 BoNT/A). In this group one BoNT/A 
animal was excluded after a possible bladder carcinoma was incidentally found at time of 
laparotomy. Within one week of injection, body weight was noted to be significantly lower 
in the BoNT/A treated group 1 week after injection with subsequent recovery by the 9-week 
time point (Figure 2, panel D). Otherwise there were no noted differences in general health 
status between the groups.
In Vivo CMG
The results from CMG testing are shown graphically in Figure 2. TBC was similar between 
groups at all time points (Figure 2, panel A). Both groups demonstrated a gradual increase in 
average TBC over the observation period. At one week after injection, the BoNT/A treated 
animals exhibited significantly longer bladder contraction duration (Figure 2, panel B) and 
significantly lower voiding efficiency (Figure 2, panel C) when compared to controls. By 3 
weeks after injection these values returned to normal and there was no longer a significant 
difference between groups with regard to voiding efficiency or bladder contraction duration.
In Vitro Contractility
The responses to EFS in longitudinal and circumferential bladder strips were not affected by 
BoNT/A (Figure 3, Top Panels). However, the responses of BoNT/A treated animals to 
carbachol stimulation were significantly enhanced at 3 weeks for both longitudinal and 
circumferential strips (Figure 3, Bottom Panels). There were no significant differences in 
KCl-induced contractility within treatment groups when compared between time points.
DISCUSSION
One week following functional denervation with 10 units BoNT/A injected into the detrusor 
muscle of female Sprague-Dawley rats, in vivo cystometry revealed increased bladder 
contraction duration and decreased voiding efficiency relative to control. However, at this 
same time point, there were no detectable differences in responses of bladder strips to any 
stimulus applied during in vitro contractility studies. Specifically, at this time point there 
were no differences following BoNT/A treatment in response to: 1) EFS, which tests bladder 
smooth muscle strip contractile response to nerve stimulation; 2) carbachol, which tests 
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bladder smooth muscle strip contractile responses to muscarinic receptor stimulation; and 3) 
KCl, which tests the maximum capability of the muscle fibers to contract. Because we are 
unable to demonstrate any differences between BoNT/A and control animals at this tissue 
level, we hypothesize that the changes in voiding at this time point are due to attempted 
compensation by the central nervous system (CNS) micturition reflex pathways. Assuming 
that the duration of voiding contraction is driven by the duration of descending micturition 
signals, it is possible that the CNS increases descending micturition signals in response to 
reduced in situ bladder contractility and emptying at this time. However, if this is indeed the 
case, compensatory attempts were insufficient and voiding efficiency was still reduced. 
Alternatively, the effects seen in our study could be the result of alterations in the afferent 
sensory signals that may potentially be affected by BoNT/A injection.
Both cystometric bladder contraction duration and voiding efficiency returned to normal by 
week 3 after injection. At the same 3-week time point, however, there was an enhanced 
response to carbachol, with no change in response to EFS during in vitro bladder strip 
testing. The enhanced response to carbachol likely reflects a compensatory increase in 
muscarinic receptors, as previously described following mechanical denervation.12
By week 6 post-injection, both in vivo cystometric and in vitro contractility results fail to 
show any differences between BoNT/A and control animals. This is in contrast to the body 
weight data, which continues to show an effect of the BoNT/A at 6 weeks. Weight loss with 
bladder injections has been reported previously and our weight data are in line with these 
previous results.11 In terms of our finding that the bladder effects are not discernable at 6 
weeks, we hypothesize that this effect may be due to an additional compensatory response 
occurring, such as the efferent sprouting that occurs in striated muscle following similar 
treatments.13 With increased efferent nerve density, the nervous system would theoretically 
be able to overcome the effect of BoNT/A to regain function prior to full recovery of the 
neuromuscular synapse.14 Another potential possibility is that the detrusor smooth muscle 
itself may be compensate by increasing gap junction formation and thereby ameliorating the 
effect of this dose of BoNT/A. It has been previously demonstrated that bladder smooth 
muscle can trigger a generalized muscle contraction with activation of only a few muscle 
cells.15 So, even if the majority of neuromuscular connections are inhibited by BoNT/A, if a 
critical mass is activated this could in theory cause a full muscle contraction. Importantly 
this increased electrical coupling of cells also occurs in the setting of detrusor instability,16 
and thus further research is needed to clarify if coupling is indeed increased in response to 
BoNT/A injection as this compensatory response could potentially worsen the underlying 
OAB/UUI.
We were surprised to see no differences in TBC between the BoNT/A and control animals. 
There is preliminary research showing that BoNT/A alters sensory activity, including 
decreases in TRPV1 and P2X3 receptor density, 17 and BoNT/A is being increasingly 
utilized clinically off label (not labeled for use by FDA) to treat bladder pain syndrome and 
similar urologic sensory disturbances supporting a sensory effect of BoNT/A.18 We may 
only conclude that our approach (dose and injection strategy) was insufficient to affect 
afferent activity to the degree that this would alter TBC. Of note, the BoNT/A group 
experienced weight loss while control animals did not. Therefore, if corrected for body 
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weight, one may argue that TBC did increase transiently (relative to total body weight) in 
BoNT/A treated animals.
This pilot study to assess the effect of BoNT/A in an intact neuromuscular system was well-
designed using both in vivo and in vitro assessment techniques over a 9-week time period of 
observation. Limitations include the small number of animals studied due to the pilot design 
and the potential effect of long-term catheter implantation on bladder function. Catheter 
implantation is a necessary requirement in this study design in order to perform repeated 
cystometric analysis over the time period of observation. We did provide antibiotic 
prophylaxis to prevent infection and each group underwent the same implantation technique 
by the same surgeon to minimize bias. Animals were acclimated to the restraint prior to 
testing and allowed sufficient recovery from anesthesia before cystometric testing was 
initiated. Additionally this technique of conscious restrained cystometry has been utilized 
successfully in our lab as well as by others to study bladder function.10,19–21
In conclusion, we have examined the effect of BoNT/A over a 9-week time period in the 
detrusor muscle of rats. Our findings suggest that shortly after BoNT/A injection, functional 
tissue responses are unchanged and an early compensatory mechanism after injection may 
be an increased duration of efferent drive mediated through supraspinal pathways. Further 
research is needed to determine if there is increased coupling between the detrusor smooth 
muscle cells and, if so, to investigate whether this persists after treatment with BoNT/A as 
this would likely have significant clinical effects with repeated BoNT/A treatments. Further 
research into the afferent effects of BoNT/A is also needed to delineate the effect of 
BoNT/A on afferent signaling pathways.
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Figure 1. In Vitro Contractility Set-Up
IVC set-up illustration demonstrating bladder tissue (large oval) mounted between 
electrodes (for electrical stimulation testing) and attached to the tensometer while being 
submerged in the bath of Krebs solution
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Figure 2. In Vivo Cystometry and Body Weight
Graphs displaying CMG data and body weight data over 9 week observation period with 
statistical significance as noted. A. True bladder capacity; B. Bladder contraction duration; 
C. Voiding efficiency; D. Body weight. Darker gray indicates BoNT/A treated animals and 
lighter gray indicates saline (control) animals.
a, cp < 0.001 for saline vs BoNT/A by Sidaks multiple comparison.
bp<0.01 for saline vs BoNT/A by Sidaks multiple comparison.
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Figure 3. In Vitro Contractility Testing
Graph of IVC results in BoNT/A treated animals by time point of IVC testing with statistical 
significance as noted. A. Response of longitudinal strips to EFS; B. Response of 
circumferential strips to EFS. C. Response of longitudinal strips to carbachol stimulation. D. 
Response of circumferential strips to carbachol stimulation.
a, band c p < 0.05 for saline vs BoNT/A by Sidaks multiple comparison.
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